House votes to repeal medical device tax

https://www.washingtonpost.com/politics/house-votes-to-repeal-medical-device-tax/2018/07/24/d786fa0e-8f9c-11e8-b769-e3fff17f0689_story.html?utm_term=.189b15308a2f

The House voted Tuesday to repeal the excise tax on medical devices, with nearly five-dozen Democrats joining all but one Republican in backing the bill.

The measure was approved on a 283-132 vote that comes before lawmakers leave Washington for their summer recess at the end of the week.

The 2.3 percent tax on some devices sold by medical manufacturers was created under the Affordable Care Act. It is not set to take effect until 2020, following a move by lawmakers to include its postponement as part of the deal that ended a government shutdown in January. But lawmakers of both parties have long sought to repeal the tax, arguing that its enactment could lead to higher prices for consumers as well as the loss of tens of thousands of manufacturing jobs.

Fifty-seven Democrats joined 226 Republicans in approving the measure Tuesday night. The path forward in the Senate remains uncertain.

 

 

21st Century Cures Act: 4 health industry impacts summarized

http://www.healthcaredive.com/news/21st-century-cures-act-explained/431491/

On Wednesday, the Senate voted 94-5 to pass the long-awaited 21st Century Cures Bill. As it has backing from the current White House administration, President Barack Obama is expected to sign the legislation into law.

The law has been called the “most important bill of the year” by Senator Lamar Alexander (R-TN), as Politico Pulse reported Tuesday. The bill, while bipartisan, is not without controversy. While the House version of the legislation passed swimmingly with a vote of 392-26, the bill did have its share of opponents in the Senate– including Sen. Elizabeth Warren (D-MA) and Sen. Bernie Sanders (I-VT) – who think the bill is too favorable to pharmaceutical companies. Both Sanders and Warren were among the five Senators to vote against the measure.

And as Modern Healthcare’s Merrill Goozner notes in an editorial, it’s likely the true impact of the bill won’t be known right away but will be realized as the years pass. “The final details of the 996-page legislation…weren’t known until five days before it passed,” Goozner wrote.

About three years of work and efforts from 1,400 lobbyists for 400 companies went into the making of this $6.3 billion package. It seeks to deliberately speed medical research and treatments. Because seemingly no healthcare legislation can be a reasonable length (it’s about 90 pages longer than the ACA) and because nothing in healthcare is simple, we’ve summarized some of the notable implications of the bill in four buckets: Health IT, mental health, FDA reform and research and care funding.

The players who are set to influence Trump on health care

The players who are set to influence Trump on health care

It’s customary in the nation’s capital to hail members of the incoming administration by telling everyone in town how close you are to them. So many in conservative Washington lobbying circles and elsewhere are busy touting their relationships with President-elect Donald Trump and his advisers.

There’s a benefit to proximity to power, especially now. At a time when nobody really knows how the Trump administration will regulate drugs and medical devices, fund scientific research, or repeal or replace the Affordable Care Act, relationships with the newcomers are viewed as critical to getting one’s issues on the table.

Donations don’t hurt, either.

Trump’s transition team is a moving train, so influencers are likely to jump aboard fast. Here’s STAT’s look at people and organizations in health care and science who are likely to have influence with a Trump presidency — and who else might benefit.